Medulloblastoma
A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)
Drugs by status
Approved for this indication (1)
Phase 4 trials (7)
Phase 3 trials (13)
Phase 2 trials (70)
- mannitol
- s-methionine
- thalidomide
- decitabine
- 90y-dota-tyr3-octreotide
- ly-3023414
- axitinib
- plerixafor
- mk-1775
- olaparib
- busulfan
- bvd-523
- irinotecan
- silmitasertib
- erdafitinib
- vismodegib
- gemcitabine
- lapatinib
- indoximod
- Filgrastim
- nivolumab
- potassium iodide
- larotrectinib
- nifurtimox
- nktr-214
- palbociclib
- pemetrexed
- pep-cmv
- acetaminophen
- zarnestra
- +40 more
Phase 1 trials (62)
- azacitidine
- prexasertib
- abemaciclib
- apx005m
- atovaquone
- azurin-derived cell-penetrating peptide p28
- urea
- lenalidomide
- cilengitide
- cudc-907
- valproic acid
- ef5
- g207
- tacrolimus
- trametinib
- hydrocortisone
- imiquimod
- autologous natural killer cells
- ispinesib
- pembrolizumab
- ribociclib
- leq-506
- mebendazole
- o6-benzylguanine
- panobinostat
- ibrutinib
- ro4929097
- sgt-53
- sirolimus
- mycophenolate
- +32 more
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (13)
- National Cancer Institute (NCI)
- University of Hamburg
- University of Leicester
- University of Michigan
- University of Toronto
- University of Bonn
- Wayne State University
- Curie Institute
- University of Duisburg-Essen
- Children's National Medical Center
- Ostra Sjukhuset
- Deutsche Kinderkrebsstiftung
- St. Jude Children's Hospital
Organization Involved with Phase 2 Indications (67)
- Celgene
- Eli Lilly
- Genentech
- Pfizer
- Novartis
- Bayer
- BioInvent International AB
- Cortice Biosciences, Inc.
- Oncurious NV
- National Institutes of Health (NIH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of Pennsylvania
- Augusta University
- Baylor University
- Center Eugene Marquis
- Centre Georges Francois Leclerc
- Centre Hospitalier Universitaire de Nīmes
- Centre Leon Berard
- Children's Cancer and Leukaemia Group
- Eastern Cooperative Oncology Group
- Emory University
- Florida International University
- Johns Hopkins University
- Newcastle University
- Oregon Health and Science University
- Pediatric Brain Tumor Consortium
- Southwest Oncology Group
- Stanford University
- University of Florida
- University of Iowa
- +37 more
Organization Involved with Phase 1 Indications (35)
- Curis
- Oncoceutics, Inc.
- Vyriad, Inc.
- Apexigen, Inc.
- Cornell University
- Duke University
- University of Washington
- University of South Carolina
- Mayo Clinic
- University of California, San Francisco
- Medical University of South Carolina
- University of Minnesota
- NewLink Genetics Inc
- Sumitomo Dainippon
- City of Hope National Medical Center
- University of Texas at Houston
- University of Alabama, Birmingham
- The Andrew McDonough B+ Foundation
- No More Kids With Cancer
- The Matthew Larson Foundation for Pediatric Brain Tumors
- Annias Immunotherapeutics, Inc.
- CURE Childhood Cancer, Inc.
- Musella Foundation
- Memorial Sloan-Kettering Cancer Center
- Midatech Pharma
- The Pacific Pediatric Neuro-Oncology Consortium
- Solving Kids’ Cancer
- A Kids Brain Tumor Cure
- American Lebanese Syrian Associated Charities
- Ty Louis Campbell Foundation
- +5 more
Organization Involved with Other Experimental Indications (3)